Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2003
11/20/2003US20030215508 Sustained release portion of unit dose containing guaifenesin, dextromethorphan and a release-delaying matrix contains a hydrophilic polymer and a water insoluble polymer, immediate release portion containing guaifenesin
11/20/2003US20030215507 Extended release formulation
11/20/2003US20030215506 Methods and compositions for enhancement of creatine transport
11/20/2003US20030215505 Rapidly disintegrating tablet for oral administration containing a compacted mixture of methylcellulose having specific viscosity and an edible calcium salt
11/20/2003US20030215504 Directly compressible acetaminophen compositions
11/20/2003US20030215503 Palatable chewable tablet
11/20/2003US20030215496 Solid carrier includes a hydrophililc surfactant and a drug
11/20/2003US20030215495 Antihistamine formulations for soft capsule dosage forms
11/20/2003US20030215494 Administering a dose of a lipid-drug enhancer liposomal complex; and in sequence, administering a dose of lipid-anicancer drug liposomal complex via aerosolization from a nebulizer, to inhibit growth of lung metastases
11/20/2003US20030215493 Composition and method for dermatological treatment
11/20/2003US20030215492 Administering a mammalian host for treating a disease caused by proliferation of eukaryotic cells a formulation containing a complex of lipid and a drug 7-ethyl-10-hydroxycamptothecin
11/20/2003US20030215491 Method and composition for rapid delivery of bioactive compounds to the systemic circulation via the nasal membrane
11/20/2003US20030215489 Chemosensitizing with liposomes containing oligonucleotides
11/20/2003US20030215487 Adhesive comprises N-methylpyrrolidone and oleoylsarcosine as penetration enhancers and polyurethane backing for application to non-scrotal skin
11/20/2003US20030215473 Comprises fractionated oat oil comprising galactolipids as emulsifier
11/20/2003US20030215472 Such as dimethylmyristamide for use in deodorants/cosmetics/ antiperspirants
11/20/2003US20030215465 Use of conjugated acid derivatives
11/20/2003US20030215462 Use of UGT inhibitors to increase bioavailability
11/20/2003US20030215461 Immunogenic composition comprising adenyl cyclase-hemolysin protein, or portion thereof, strain of Bordetella chosen from B.pertussis, B.parapertussis or B.bronchiseptica, bacterial extract containing expression product of bordetella vrg genes
11/20/2003US20030215455 Composed of reducing agent to neutralize oxidizing water sanitizers of 0.0002 percent and coloring agent to provide visual reference for aiding in determining administration of vaccine to livestock of 0.00-99.9998 percent by weight
11/20/2003US20030215452 Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules
11/20/2003US20030215448 Compositions and methods for treating hyperimmune response in the eye
11/20/2003US20030215446 CATT-tetranucleotide repeat polymorphism at position-817 of the human Mif gene that functionally affects the activity of the Macrophage Inhibitory Factor (MIF) promoter in gene reporter assays
11/20/2003US20030215438 Enzyme treatment of foodstuffs for celiac sprue
11/20/2003US20030215430 Composition for the treatment and prevention of endothelial dysfunction
11/20/2003US20030215428 Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
11/20/2003US20030215414 Compositions comprising a combination of a free sphingoid base and a ceramide and uses thereof
11/20/2003US20030215413 Compositions containing stabilized retinoid
11/20/2003US20030215408 Combination antiperspirant and antimicrobial composition
11/20/2003US20030215407 An amino acid, especially a carboxylated, acidic amino acid; a skin lightening agent; a carrier; a strong acid, to solubilize the amino acid; and a base to maintain the composition at a pH of 0.5-8.
11/20/2003US20030215401 Potassium or strontium salt as a nerve desensitizing agent; tubule blocking agent, that may be a hydrolyzed long-chain olefin-maleic anhydride copolymer
11/20/2003US20030215397 Method of treatment of skin diseases related to microbial antigens in the skin
11/20/2003US20030215396 Method for the production of propellant gas-free aerosols from aqueous medicament preparations
11/20/2003US20030215395 Cationic amine polymer, cationic peptide or cationic carbohydrate and at least one degradable linker molecule connecting said cationic molecules in a branched arrangement
11/20/2003US20030215388 Can be administered in conjunction with radiation or chemotherapeutic agents.
11/20/2003US20030214409 System and method for transparent early detection, warning, and intervention during a medical procedure
11/20/2003DE20314191U1 Tablet or other solid dosage form for use in human and veterinary medicine comprises phenoxymethyl penicillin potassium and just one excipient with strong lubricating properties
11/20/2003CA2763775A1 Bisphosphonic acids for the treatment and prevention of osteoporosis
11/20/2003CA2511749A1 Surface treatment of sars-infected lung
11/20/2003CA2492394A1 Induction of antigen specific immunologic tolerance
11/20/2003CA2492044A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003CA2490989A1 Methods and compositions for the treatment of graft failure
11/20/2003CA2486075A1 Abuse-resistant opioid solid dosage form
11/20/2003CA2485755A1 Purified composition of bispecific molecules and methods of production
11/20/2003CA2485753A1 Benzimidazole derivatives
11/20/2003CA2485567A1 Treatments with autologous fibroblast
11/20/2003CA2485527A1 Substituted pyrroline kinase inhibitors
11/20/2003CA2485431A1 Platinum complexes having antitumor activity
11/20/2003CA2485389A1 Formulations useful in the treatment of male and female impotence
11/20/2003CA2485380A1 A pharmaceutical composition for the treatment of seborrhea containing ovalicin
11/20/2003CA2485373A1 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003CA2485264A1 Formulations useful in the treatment of male and female impotence
11/20/2003CA2485262A1 Novel crystalline forms of gatifloxacin
11/20/2003CA2485256A1 Pathogen vaccines and methods for using the same
11/20/2003CA2485252A1 Methods of using thiazolidine derivatives to treat cancer or inflammation
11/20/2003CA2485148A1 Pyrimidinone compounds, compositions and methods
11/20/2003CA2485146A1 Deoxycholic acid derivatives for the treatment of acute dysfunctions of portal and hepatic venous circulation
11/20/2003CA2485130A1 Novel enantiomers of tetrahydroisoquinoline derivatives and their pharmaceutically acceptable salts, their preparations and pharmaceutical compositions
11/20/2003CA2485083A1 Hexahydro-pyridazine-3-carboxylic acid derivatives, pharmaceutical compositions containing same and preparation methods thereof
11/20/2003CA2484968A1 Substituted piperazine as melanocortin receptors ligands
11/20/2003CA2484891A1 Conjugates comprising central nervous system active drug
11/20/2003CA2484835A1 Complex of organic medicines and beta-cyclodextrin derivatives and its preparing process
11/20/2003CA2484829A1 Methods and compositions for treating tinea versicolor using combinations of retinoids and certain antifungals
11/20/2003CA2484827A1 Anti-rhinovirus active agents
11/20/2003CA2484815A1 Cascade esters of camptothecins and methods of treating cancer using these compounds
11/20/2003CA2484758A1 Extended release tablets comprising felodipine
11/20/2003CA2484736A1 Gallocatechin gallate-containing composition
11/20/2003CA2484641A1 A method to improve surface properties of pharmaceutical tablets
11/20/2003CA2484637A1 Nanoparticulate nystatin formulations
11/20/2003CA2484276A1 Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases
11/20/2003CA2484144A1 Eif-5a nucleic acids for inhibiting apoptosis
11/20/2003CA2483991A1 Substantially pure solid form of the enol tautomer of 3-indolylpyruvic acid for use in the treatment of central nervous system disturbances
11/20/2003CA2483914A1 Capsules for dry powder inhalers and methods of making and using same
11/20/2003CA2483882A1 Fenugreek seed bio-active compositions and methods for extracting same
11/20/2003CA2483696A1 Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
11/20/2003CA2483101A1 Cell proliferating agents
11/20/2003CA2483046A1 Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
11/20/2003CA2482541A1 Use of valsartan or its metabolite to inhibit platelet aggregation
11/20/2003CA2480488A1 Novel diazabicyclic biaryl derivatives
11/20/2003CA2480378A1 Novel azacyclic ethynyl derivatives
11/20/2003CA2462203A1 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/20/2003CA2451081A1 Adenosine a<sb>3</sb> receptor modulators
11/19/2003EP1362919A1 Slowly digestible starch product
11/19/2003EP1362916A2 Human tumor necrosis factor delta and epsilon
11/19/2003EP1362885A1 Antimicrobially treated material and methods of preventing coloring thereof
11/19/2003EP1362869A1 Resistant starch prepared by isoamlase debranching of low amylose starch
11/19/2003EP1362857A1 (S)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinymethyl]-4-piperidinyl]benzamide for treating gastrointestinal motility disorders
11/19/2003EP1362855A1 Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
11/19/2003EP1362849A2 Process for production of piperidine derivatives
11/19/2003EP1362848A1 Process for the preparation of vitamin D derivatives
11/19/2003EP1362846A1 Aminoethanol derivatives
11/19/2003EP1362844A1 Benzylamine analogue
11/19/2003EP1362600A1 Pharmaceutical compositions containing decoy and method of using the same
11/19/2003EP1362598A1 Active oxygen generator containing photosensitizer for ultrasonic therapy
11/19/2003EP1362597A1 Antigenic peptides derived from telomerase
11/19/2003EP1362594A1 Anti-stress agents
11/19/2003EP1362593A1 Pharmaceutical composition for diabetic neuropathy
11/19/2003EP1362592A1 Use of 2-hydroxy-4-trifluoromethylbenzoic acid derivatives as inhibitors of the activation of the nuclear transcription factor NF-kB
11/19/2003EP1362591A1 Use of a composition containing 5-androstene-3 beta, 17-alpha diol
11/19/2003EP1362590A1 Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
1 ... 5271 5272 5273 5274 5275 5276 5277 5278 5279 5280 5281 5282 5283 5284 5285 5286 5287 5288 5289 5290 5291 ... 7860